Welcome to our dedicated page for BNB PLUS SEC filings (Ticker: BNBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BNB Plus Corp. filings document a Nasdaq-listed common stock issuer with recurring disclosures on capital structure, stockholder approvals, governance, registration statements, and listing compliance. Form 8-K reports cover matters such as stockholder votes on reverse stock split authority, warrant-related share issuance approvals, Nasdaq minimum-bid-price compliance notices, and board changes.
Proxy materials describe special meeting proposals, voting mechanics, authorized-share considerations, and board authority requested from stockholders. Securities Act registration statement amendments address securities offered from time to time, issuer classification, offering mechanics, and related disclosure controls for the company’s public capital structure.
BNB Plus Corp. has transformed into a digital asset treasury company centered on holding and actively managing BNB, the native cryptocurrency of the Binance ecosystem, while continuing to develop its LineaRx synthetic DNA and RNA production platforms for potential sale or licensing. The company raised $26.8M in a private placement involving cash, stablecoin and OBNB trust units, and structured warrants that could add up to $30.8M in future gross proceeds if exercised. It has signed a five-year discretionary asset management mandate and a separate strategic advisory agreement with related-party affiliates, plus a three-year, multi-million-dollar consulting and sponsorship arrangement to support its BNB-focused strategy.
To fund this shift, BNB Plus exited DNA tagging and clinical lab testing, closed its ADCL lab, and executed multiple restructurings that reduced headcount by 72% and are projected to cut payroll by about 70% versus the prior year, while incurring one-time severance and impairment charges. The LineaRx business now concentrates on its LineaDNA and LineaIVT technologies for therapeutic DNA and mRNA manufacturing, competing with large established players. As of December 15, 2025, the company had 4,365,541 shares of common stock outstanding and held about 18,830 BNB, including direct holdings and exposure via OBNB trust units, reflecting a significant balance-sheet commitment to BNB amid evolving and uncertain digital asset regulation.
BNB PLUS CORP. reported that its Chief Executive Officer, as an officer of the company, acquired two stock option positions on December 15, 2025.
One is an incentive stock option and the other a non-qualified stock option, each giving the right to buy 42,194 shares of common stock at an exercise price of $2.52 per share, expiring on December 15, 2035. The options were acquired at a price of $0 and are reported as held directly. According to the disclosure, these options vest 25% per quarter, beginning 90 days from the grant date.
BNB Plus Corp reported that its chief financial officer, Beth Jantzen, received equity awards in the form of stock options on 12/15/2025. She was granted an incentive stock option to buy 42,194 shares of common stock and a separate non-qualified stock option to buy 42,194 shares, each with an exercise price of $2.52 per share and an expiration date of 12/15/2035.
The options were granted at a price of $0 for the options themselves, giving her the right, but not the obligation, to purchase BNB Plus Corp common stock at $2.52 in the future. According to the disclosure, the options vest 25% per quarter, beginning 90 days from the grant date, and are held with direct ownership.
BNB Plus Corp. held a special meeting of stockholders on December 12, 2025, where investors approved three capital-related proposals. Stockholders first approved, under Nasdaq Listing Rules 5635(a) and 5635(d), the exercisability of certain pre-funded warrants and common stock purchase warrants, and the issuance of the common shares underlying those securities, which were issued under a securities purchase agreement dated September 29, 2025.
They also approved an amendment to the Certificate of Incorporation to increase authorized common shares from 200,000,000 to 500,000,000, expanding the number of shares the company may issue in the future. In addition, stockholders approved an amendment to the 2020 Equity Incentive Plan to increase the shares reserved for equity awards by 5,000,000. Each proposal received sufficient votes for approval, indicating broad support for the company’s capital and incentive plans.
BNB PLUS CORP. director Joshua Kruger filed an initial Form 3 reporting his ownership in the company. As of the event date of 11/06/2025, he beneficially owns 75,302 shares of common stock directly.
He also holds Series E-1 warrants that are exercisable beginning on 10/03/2025 and expiring on 10/03/2030, covering 75,302 shares of common stock at an exercise price of $3.82 per share, also held directly.